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Background/Aims. Intraperitoneal intraoperative hyperthermic chemotherapy (HIPEC) has been used in the treatment of ovarian
cancer. The purpose of the study is to determine the eﬃcacy of HIPEC after cytoreductive surgery in advanced ovarian cancer.
Patients/Methods. From 2006 to 2010 patients with advanced ovarian cancer were enrolled in a prospective nonrandomized study
to undergo cytoreductive surgery combined with HIPEC. Clinical and histopathological variables were correlated to hospital
mortality, morbidity, survival, and recurrences. Results. The mean age of 43 women was 59.9 ± 13.8 (16–82) years. The hospital
mortality and morbidity rate were 4.7% and 51.2%, respectively. Complete cytoreduction was possible in 69.8%. The overall 5-
year survival rate was 54%. The prognostic indicators of survival were the extent of prior surgery (P = 0.048) and the extent of
peritoneal dissemination (P = 0.011). The recurrence rate was 30.2%. Conclusions. Maximal cytoreductive surgery combined with
HIPEC is a well-tolerated, feasible, and promising method of treatment in advanced ovarian cancer.
1.Introduction
Epithelial ovarian cancer is usually diagnosed when the tu-
mor has already disseminated at the peritoneal surfaces.
The standard treatment at this stage is cytoreductive surgery
combined with systemic chemotherapy [1]. Although ovar-
ian cancer is one of the most chemosensitive tumors and
complete response is achieved in 80% [2], the majority of
patients develop recurrence, and long-term survival is poor
[3–5]. The most signiﬁcant prognostic variable of survival
has been shown to be the maximal diameter of the residual
tumor [6].
Even if a complete cytoreduction has been performed
with no macroscopically visible tumor, microscopic tumor
will always remain at the peritoneal surfaces. A poten-
tially therapeutic result is possible if the residual tumor
is eradicated. Intraperitoneal chemotherapy is eﬀective in
eradicating cancer emboli with maximal diameter less than
2-3mm.
In practice, hyperthermic intraperitoneal intraoperative
chemotherapy (HIPEC) has been used in locally advanced
epithelial ovarian cancer as an adjuvant treatment after cy-
toreductive surgery with promising results [7–11].
The purpose of the prospective nonrandomized study is
to determine the eﬃcacy of HIPEC after maximal cytore-
ductive surgery in women with locally advanced epithelial
ovarian cancer.
2. Patients/Methods
Womenwithlocallyadvancedepithelialovariancancer(both
primary and recurrent) were enrolled from 2006 to 2010 for
maximal cytoreductive surgery with standard peritonectomy
procedures combined with HIPEC.
The diagnosis was established by physical examination,
hematological-biochemical examinations, tumor markers
(CEA, CA 19-9, CA-125), and abdominal and thoracic CT2 Journal of Oncology
scan.Theperformancestatus,age,theextentofpriorsurgery,
the extent and distribution of peritoneal dissemination,
the tumor volume, the completeness of cytoreduction (CC
score), the presence of ascites, and the presence of metastatic
disease were assessed and correlated to survival, recurrences,
sites of recurrence, morbidity, and hospital mortality.
The physical status of the patients was assessed using the
Karnofsky performance scale.
The extent of prior surgery was assessed using prior
surgery score (PSS) [12]. The score was deﬁned as PSS-0
when no surgery had been performed for cancer, as PSS-1
when biopsy only or surgery in one abdominopelvic region
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had been performed, and as PSS-3 when surgery had been
performed in more than 5 regions.
The extent and distribution of peritoneal dissemination
was assessed by using the peritoneal cancer index (PCI). Two
transverse and two sagittal planes divided the abdomen in 9
regions. The upper transverse plane was the lowest part of
the costal margin and the lower plane the anterior superior
iliac spine. The small bowel was assessed as a separate entity,
divided into 4 segments (upper and lower jejunum, upper
and lower ileum). The peritoneal cancer index was the sum
of the tumor volume in each one of the 13 abdominopelvic
regions.Thetumorvolumewasassessedassmallifthelargest
tumor nodules were <0.5cm in their largest diameter and as
large if the nodules were >0.5cm [12].
The completeness of cytoreduction was indicated by CC-
0 to CC-3. A CC-0 indicated that no visible tumor had
been left behind after surgery. A CC-1 indicated that the
residual tumor was <0.25cm in its largest diameter. If after
cytoreductive surgery tumor >0.25cm and <2.5cm was left
behind, it was indicated as CC-2 surgery, and when the
largest diameter of the residual tumor was >2.5cm this
was indicated by CC-3 surgery. Only CC-0 operations were
considered complete cytoreductions [12].
The presence of metastatic disease to remote lymph
nodes that had no anatomic relationship to the primary site
was considered as distant metastasis.
During the immediate postoperative period all patients
were assisted in an intensive care unit for 24 hours. If
early postoperative intraperitoneal chemotherapy (EPIC)
was used then the patients were assisted for 5 days in the
ICU. Chemotherapy toxicity was scored using the WHO
criteria. Treatment-related morbidity was classiﬁed as grade
1: uncomplicated patient, grade 2: minor complications,
grade 3: major complications requiring intervention (ICU
readmission or reoperation), and grade 4: in-hospital mor-
tality.
The protocol was approved by the Ethical Committee
of the hospital, and an informed consent was signed by all
patients.
Patients with: (a) acceptable physical status (Karnofsky
performance status >50%), (b) normal liver and renal
function, (c) normal hematological proﬁle, and (d) no
evidenceofothermalignancyoratriskforrecurrence,except
for basal cell carcinoma or in situ cervix cancer properly
treated, were considered eligible for maximal cytoreductive
surgery and HIPEC.
2.1. Treatments. The patients underwent surgery with the
intention of performing a complete cytoreduction. The stan-
dard peritonectomy procedures used for maximal cytore-
duction of the tumor volume were pelvic peritonectomy,
greater omentectomy with or without splenectomy, lesser
omentectomy, right and left subdiaphragmatic peritonec-
tomy, cholecystectomy with resection of the omental bursa,
and parietal peritonectomy. Resection of other organs, small
and/or large bowel, and stomach was performed if necessary
for achieving complete cytoreduction.
After the resection of the tumor and before the recon-
struction of the gastrointestinal tract HIPEC was performed
using the Coliseum technique [13] for 90min if cisplatin
(50mg/m2)a n dd o x o r u b i c i n( 1 5m g / m 2) were instilled and
for60minifgemcitabine(1000mg/m2)wasinstilledat42.5–
43◦C. Gemcitabine was used for platinum-resistant women.
HIPEC was performed via a circuit of 4 drains (2 inﬂow
and 2 outﬂow) that were connected to an extracorporeal
sterile circuit in which a 3 lit perfusate was circulated by
two peristaltic pumps (one inﬂow and one outﬂow) at a
ﬂow rate of 2lit/min. The sterile circuit was heated by a
thermal exchanger connected to the heating circuit. Systemic
chemotherapy was used in those patients that underwent
CC-1orCC-2surgeryorthosethathadsystemicorrecurrent
disease. Platinum-resistant patients were considered those
women that did not respond or developed recurrence in less
than 6 months after initial systemic chemotherapy.
2.2. Followup. The patients were followed up every 4 months
during the ﬁrst year after surgery and every 6 months
later with physical examination, hematological-biochemical
examinations, tumor markers (CEA, CA-125), and CT
abdominal scan. The recurrences and the sites of recurrence
were recorded.
2.3. Statistical Analysis. Statistical analysis was made using
the SPSS (Statistical Package for Social Sciences). The
proportions of patients with a given characteristic were com-
pared by chi-square analysis or by Pearson’s test. Diﬀerences
in the means of continuous measurements were tested by the
Student’s t-test. The survival curves were obtained using the
Kaplan-Meier method, and the comparison of curves was
calculated using the log-rank test. Cox regression analysis
made possible multiple analysis of survival. Logistic regres-
sion analysis made possible multiple analysis of recurrence
and morbidity. A two-tailed P value <0.05 was considered
statistically signiﬁcant.
3. Results
From 2006 to 2010, 43 women with primary or recurrent
ovarian cancer were enrolled in the study and underwent
maximal cytoreductive surgery and HIPEC. The mean age of
thepatientswas59.9±13.8(16–82)years.Thecharacteristics
of the patients are summarized in Table 1. Twenty patients
(46.5%) had recurrent ovarian cancer and underwent sec-
ondary cytoreduction. The mean PCI was 15.05 (3–33).
Extensive peritoneal dissemination was found in 20 (46.5%)Journal of Oncology 3
Table 1: Characteristics of the patients.
Number of patients %
Performance status
90–100% 34 79.1
70–80% 8 18.6
50–60% 1 2.3
Tumor volume
Large volume 34 79.1
Small volume 9 20.9
PSS
PSS-0 23 53.5
PSS-1 4 9.3
PSS-2 8 18.6
PSS-3 8 18.6
PCI
PCI < 15 23 53.5
PCI > 15 20 46.5
CC
CC-0 30 69.8
CC-1 11 25.6
CC-2 2 4.7
Ascites 27 62.8
Remote lymph nodes 4 9.3
Systemic chemotherapy 23 53.5
Morbidity 22 51.2
Hospital mortality 2 4.7
Recurrence 13 30.2
women,andtheirintraoperativePCIwascalculated>15.The
performed peritonectomy procedures are listed in Table 2.
In 4 patients (9.3%) lymph nodal involvement was found
in remote sites that had no anatomical relationship to the
primary site. Despite the extent of peritoneal dissemination
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with recurrent disease received gemcitabine during HIPEC
because they were considered to be platinum resistant, and
15 patients received cisplatinum + doxorubicin.
3.1. Hospital Morbidity and Mortality. Grade 1 morbidity
was recorded in 21 patients (48.8%). Grade 2 morbidity
was recorded in 16 patients (35.2%) that had pleural
eﬀusion, neutropenia grade II that did not require medi-
cal treatment, pneumonitis, ﬁstulas, and wound infection,
grade 3 morbidity was recorded in 4 patients (9.3%) that
had enterocutaneous ﬁstulas, and grade 4 morbidity in 2
patients (4.7%) with anastomotic failure that developed
sepsis (Table 3).
3.2. Histopathology. Histopathology revealed serous adeno-
carcinomas in 25 cases (58.1%), cystadenocarcinomas in 8
cases (18.6%), endometrioid in 6 cases (13.9%), and clear-
cell carcinomas in 4 cases (9.4%).
Table 2: Peritonectomy procedures.
Peritonectomy Number of
procedures %
Right subdiaphragmatic 21 8.7
Left subdiaphragmatic 13 5.4
Greater omentectomy 37 15.4
Lesser omentectomy 12 5
Splenectomy 20 8.3
Pelvic peritonectomy 43 17.8
Cholecystectomy + resection of the
omental bursa 23 9.5
Right parietal 20 8.3
Left parietal 20 8.3
Segmental intestinal resection 12 5
Right colectomy 6 2.5
Subtotal colectomy 8 3.4
Abdominopelvic lymph node resection 2 0.8
Antrectomy 4 1.6
Table 3: Complications.
Complication Number of patients %
Grade I 21 48.8
Grade II
Pleural eﬀusion 2 4.7
Wound infection 7 14.2
Neutropenia grade II 3 6.9
Pneumonitis 2 4.7
Enterocutaneous ﬁstulas 2 4.7
Grade III 4 9.3
Enterocutaneous ﬁstulas
Grade IV 2 4.7
Anastomotic failure
3.3. Survival. The overall 5-year survival rate was 54%
(Figure 1) .T h em e a ns u r v i v a lw a s3 7± 6 months. By
univariate analysis it was found that the completeness of
cytoreduction (P = 0.0001), the PCI (P = 0.0022), the PSS
(P = 0.0265), the presence of ascites (P = 0.0476), and the
use of systemic chemotherapy (P = 0.0383) were related
to survival. 5-year survival rate for patients with complete
cytoreduction was 62.5% (Figure 2), for those with a PCI
< 15, 70% (Figure 3), and for those with a PSS-0, 82.5%
(Figure 4).
By multivariate analysis it was found that the prognostic
indicators of survival were the PSS (HR = 5.844, P = 0.048,
95% CI = 1.017–33.588) and the PCI (HR = 20.425, P =
0.011, 95% CI = 1.975–211.22).
3.4. Followup. No patient was lost during followup. During
followup 13 patients (30.2%) developed recurrence. The
recurrence was distant in 5 patients and locoregional in 8.
Of the 43 patients, 28 (65.1%) are alive without evidence4 Journal of Oncology
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Figure 1: Overall 5-year survival rate.
Time (months)
60 50 40 30 20 10 0
C
u
m
 
s
u
r
v
i
v
a
l
1.2
1
0.8
0.6
0.4
0.2
0
CC-0
CC-1, CC-2
Figure 2: Survival according to CC score. The continuous line is
for patients with CC-O and the dotted line is for patients with CC-
1, CC-2 (P = 0.0001).
of disease, 3 patients (7.1%) died for reasons unrelated to
disease, 8 patients (18.6%) died because of recurrence, and 2
patients (4.6%) are alive with recurrence. By univariate anal-
ysis the recurrence was found to be related to pathological
values of CA-125 (P = 0.022). No other variable was found
to be related to the development of recurrence. The patients
that received cisplatin + doxorubicin were not oﬀered longer
survival compared to those that received gemcitabine during
HIPEC.
4. Discussion
The survival rate of epithelial ovarian cancer has improved
because the tumor is one of the few most chemosensitive
to platinum derivatives [2]. However, the long-term survival
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Figure 3: Survival according to PCI. The continuous line is for
patients with PCI < 15 and the dotted line for patients with PCI
> 15 (P = 0.0022).
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Figure 4: Survival according to PSS. The continuous line is for
patientswithPSS-0andthedottedlineforpatientswithPSS-1,PSS-
2, and PSS-3 (P = 0.0265).
has still been poor and has not exceeded 20% [3–5]. New
promising treatment strategies implemented the last decade
give hope that survival will be improved.
T h em o s tp o w e r f u lt o o li nt h et r e a t m e n to fo v a r i a nc a n -
cer with peritoneal dissemination is cytoreductive surgery.
Complete (CC-0) or near-complete (CC-1) cytoreduction is
feasibleinmorethan75%ofthecases[14]ifmaximalcytore-
ductive surgery with standard peritonectomy procedures is
used [15]. Extensive peritoneal carcinomatosis in ovarian
cancer is an unfavorable prognostic indicator. However,
patients with high values of PCI are not necessarily excluded
from surgical intervention. The PCI can be approximately
calculated preoperatively by CT abdominal scanning. ThereJournal of Oncology 5
are limitations in the accuracy and speciﬁcity of the preoper-
ative evaluation of the PCI using the CT scan. Tiny nodules
at the peritoneal surfaces of the bowel are rarely depicted at
the CT scan, and the preoperative calculation of the PCI is
not always accurate. The caveat for complete cytoreduction
is the extent of dissemination at the peritoneal surfaces of
the bowel. This is the reason why 8 subtotal colectomies
were performed in the present study. This aggressive method
has been successfully used for the treatment of mucinous
peritoneal carcinomatosis from nongynecologic cancer [16].
Therefore, high rate of complete (69.8%) or near-complete
cytoreduction (25.6%) was possible although in 20 patients
the PCI was >15 which is in agreement with other reports
for patients with primary or recurrent ovarian cancer [7–
9, 11, 14, 17, 18].
One of the most signiﬁcant variables of survival is the
extent of prior surgery. It has not been given much attention
and only in one study that the PSS has been reported as
ap r o g n o s t i cv a r i a b l eo fs u r v i v a l[ 7]. The extent of prior
surgery is probably related to the extent of tumor cell
implantation at the peritoneal surfaces of the abdomen. It
may also imply that the most signiﬁcant variable for long-
term survival is the ﬁrst cytoreductive operation. In the
present study it has been found that the initially diagnosed
patients (PSS-0) have 82.5% 5-year survival rate. The extent
of prior surgery and the extent of peritoneal carcinomatosis
have also been identiﬁed as prognostic variables of survival.
Paradoxically the completeness of cytoreduction has not
been identiﬁed as a prognostic indicator although it has been
found to be strongly related to survival [1, 6, 7, 9, 11].
Intraperitoneal chemotherapy has been documented as
the standard treatment of peritoneal malignancy from nong-
ynecologic cancer [19–23]. Intraperitoneal chemotherapy
has also been used in ovarian cancer [24]a n dc o m p a r e dt o
intravenous chemotherapy has shown to improve survival in
patients who had undergone in the past optimal cytoreduc-
tive surgery.
Themethodhasbeenperformedwiththeuseoftheopen
abdominal technique (Coliseum technique) that enables the
uniform distribution of the heat and the cytostatic drugs
in the abdominal cavity. In addition, during perfusion the
surgeon has the advantage to surgically eradicate small
nodules located at the mesentery of the small bowel and as
a consequence to shorten the operative time.
Severe morbidity (grade 3 and 4) has been recorded
in 6 patients (14%). It is obvious that the most severe
complication is the anastomotic failure. Anastomotic failure
has been reported in other series as the most frequent
complication [8, 9, 25]. Cisplatin has been incriminated to
impair anastomotic healing in animal studies [26]i nc o n -
trast to local hyperthermia that has not [27]. As a conse-
quence, the failures may be attributed either to cisplatin
or to the immediate restoration of the gastrointestinal tract
after low-anterior resection particularly in those cases with
preoperative partial intestinal obstruction. The importance
of intestinal obstruction and the avoidance of immediate
restoration of the gastrointestinal tract has been emphasized
[9] resulting in signiﬁcant decrease of anastomotic failures
[28]. Therefore a protective colostomy seems to be a
reasonable solution. Other severe complications as intra-
abdominal abscess or sepsis or postoperative bleeding are
infrequent [8, 9, 25].
Severe side eﬀects attributed to HIPEC have not been
recorded. Grade 3/4 toxicity is rare and does not exceed 5%
[25]. Only 3 patients have had grade II transient neutropenia
requiring no speciﬁc treatment.
5. Conclusions
Maximal cytoreductive surgery with standard peritonectomy
procedurescombinedwithintraperitonealchemotherapyisa
well-toleratedandfeasiblemethodfortreatmentofadvanced
epithelial ovarian cancer. It appears to improve long-term
survival securing that complete or near complete cytoreduc-
tion is possible in the vast majority as well as the eradication
of the microscopic residual tumor.
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